Recently, CAR Tregs were developed to treat an experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis (MS), with an scFv targeting the myelin oligodendrocyte glycoprotein (MOG) protein, a key protein that is attacked, leading to myelin degradation. This evidence concerns the gene MOG and myeloid sarcoma.